As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.